Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 7:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 410 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sterile Water Clear all
Active, not recruiting Phase 4 Interventional

Chlorhexidine Lavage for Recurrent Urinary Tract Infection

NCT06598514
View directory record Official record
Conditions
Urinary Tract Infections, Recurrent Urinary Tract Infection
Interventions
Chlorhexidine, Sterile Water
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
55 Years to 89 Years · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 1, 2026, 7:20 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Inflammatory Challenge and Fear

NCT06630884
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD)
Interventions
Typhoid VI Polysaccharide Vaccine Injectable Solution, Saline Placebo (0.5mL injection)
Biological · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 1, 2026, 7:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension

NCT01996449
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone, Amlodipine, Microneurography, Rhythmic handgrip exercise, Sustained hand grip, Forearm blood flow, Arm cycling exercise, Cold Pressor test
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 1, 2026, 7:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

NCT03081858
View directory record Official record
Conditions
Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Urinary Bladder, Transitional Cell Carcinoma of the Bladder, Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Urinary Bladder Diseases, Urologic Diseases
Interventions
TSD-001
Drug
Lead sponsor
Lipac Oncology LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Tucson, Arizona • Bakersfield, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 1, 2026, 7:20 AM EDT
Completed Phase 2 Interventional Results available

Anti-Cytokine Therapy for Hemodialysis InflammatION

NCT03141983
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Anakinra, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 1, 2026, 7:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Trial of Two Techniques to Assess Postoperative Voiding Function

NCT02150083
View directory record Official record
Conditions
Urinary Retention
Interventions
OR retrograde fill
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 1, 2026, 7:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

TumorGlow Intraoperative Molecular Imaging (IMI)

NCT04723810
View directory record Official record
Conditions
Tumor, Solid
Interventions
Indocyanine Green
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 1, 2026, 7:20 AM EDT
Completed Phase 3 Interventional

Fluorescence-guided Surgery for Low- and High-grade Gliomas

NCT01502280
View directory record Official record
Conditions
Glioma
Interventions
5-Aminolevulinic acid (ALA), Placebo - ascorbic acid
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 1, 2026, 7:20 AM EDT
Recruiting Not applicable Interventional

Effect of Antiseptic Irrigations With 0.05% Chlorhexidine Gluconate (Irrisept) Versus Normal Saline on Fasciocutaneous Flap-Based Closure of Pilonidal Disease

NCT07321704
View directory record Official record
Conditions
Pilonidal Disease
Interventions
Irrisept (0.05% chlorhexidine gluconate), Normal Saline
Device · Other
Lead sponsor
Yosef Nasseri, MD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 1, 2026, 7:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine

NCT01290055
View directory record Official record
Conditions
Yellow Fever
Interventions
Yellow fever vaccine, Deuterium (70% enriched 2H2O) labeled water
Biological · Other
Lead sponsor
Sri Edupuganti
Other
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 1, 2026, 7:20 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy

NCT01125748
View directory record Official record
Conditions
Allergic Asthma
Interventions
Omalizumab, Placebo, Asthma therapies
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
17 Years to 70 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
100
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Bakersfield, California + 87 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 1, 2026, 7:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of Sculptra Aesthetic for Correction of Nasolabial Folds.

NCT03780244
View directory record Official record
Conditions
Nasolabial Folds
Interventions
Sculptra Aesthetic 8ml, Sculptra Aesthetic 5ml
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Solana Beach, California • Bradenton, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 1, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

NCT00439244
View directory record Official record
Conditions
Osteoporosis
Interventions
Zoledronic acid, Placebo, Teriparatide
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years to 89 Years · Female only
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Oct 1, 2026, 7:20 AM EDT
Recruiting Phase 4 Interventional

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

NCT06941870
View directory record Official record
Conditions
Factor VIII Deficiency
Interventions
Efanesoctocog alfa
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 1, 2026, 7:20 AM EDT
Completed Phase 2 Interventional

21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus

NCT03156361
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
HDV insulin lispro 100 UNIT/mL, Insulin Lispro 100 Units/mL
Drug
Lead sponsor
Diasome Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 1, 2026, 7:20 AM EDT
Completed Phase 1 Interventional Results available

The Effects of Potassium Nitrate in Reducing Dentinal Hypersensitivity

NCT01587950
View directory record Official record
Conditions
Dentinal Hypersensitivity, Dental Pain
Interventions
Potassium Nitrate, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 1, 2026, 7:20 AM EDT
Completed Phase 1 Interventional

Concentration of Itraconazole Solution in Nasal Secretions

NCT00588016
View directory record Official record
Conditions
Sinusitis
Interventions
Itraconazole
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 1, 2026, 7:20 AM EDT
Terminated Phase 3 Interventional Results available

Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients

NCT00974818
View directory record Official record
Conditions
Bladder Cancer
Interventions
Mitomycin C (MMC), Bacillus Calmette-Guerin (BCG)
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 1, 2026, 7:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of Y-3 in US Healthy Volunteers.

NCT06770491
View directory record Official record
Conditions
Safety, Tolerability, Pharmacokinetic Study in Healthy Volunteers
Interventions
Y-3 for injection, Placebo
Drug
Lead sponsor
Neurodawn Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 1, 2026, 7:20 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Randomized, Open-label, Safety Study of Subcutaneous and Intramuscular Injections of Niagen® Plus

NCT07251608
View directory record Official record
Conditions
Healthy Volunteer, Fatigue
Interventions
Niagen®Plus
Drug
Lead sponsor
ChromaDex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 1, 2026, 7:20 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke

NCT03763929
View directory record Official record
Conditions
Stroke, Acute
Interventions
Trans-Sodium Crocetinate, Placebo
Drug · Other
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
40 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 1, 2026, 7:20 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 1, 2026, 7:20 AM EDT
Terminated Phase 3 Interventional Results available

The CRISIS Prevention Study

NCT00395161
View directory record Official record
Conditions
Sepsis
Interventions
Metoclopramide, Zinc, Glutamine, Selenium, saline, sterile water, selenium, whey-protein
Drug · Dietary Supplement · Other
Lead sponsor
Michael Dean
Other
Eligibility
12 Months to 17 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2013 · Synced Oct 1, 2026, 7:20 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients

NCT07810946
View directory record Official record
Conditions
Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
Interventions
Sodium Acetate, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 1, 2026, 7:20 AM EDT